Iron modulates the activity of monoamine oxidase B in SH-SY5Y cells

Huiru Lu1, Jun Chen1,2, Hui Huang1,2

  • 1CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Multidisciplinary Research Division, Institute of High Energy Physics, Chinese Academy of Sciences (CAS), Beijing, 100049, China.

Insights

Iron exposure significantly boosts monoamine oxidase B (MAO-B) activity in neuronal cells, not MAO-A. This MAO-B activity increase, linked to neurodegenerative diseases like Parkinson's, is preventable with MAO-B inhibitors.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • Monoamine oxidase B (MAO-B) and iron accumulation are implicated in neurodegenerative conditions such as Parkinson's disease.
  • The precise relationship between iron levels and MAO-B enzymatic activity remains unclear.
  • Understanding this interaction is crucial for developing targeted therapies for iron-related neurological disorders.

Purpose of the Study:

  • To investigate the impact of iron exposure on MAO-B activity in human dopaminergic neuroblastoma cells (SH-SY5Y).
  • To determine if MAO-A or MAO-B is affected by iron.
  • To explore the potential role of MAO-B as a sensor in iron-stressed neuronal environments.

Main Methods:

  • Utilized highly sensitive and specific fluorescence probes to monitor MAO-B activity.
  • Exposed SH-SY5Y cells to ferric and ferrous iron ions.
  • Administered MAO-B inhibitors, such as pargyline, to assess the specificity of iron's effect.

Main Results:

  • Both ferric and ferrous ions significantly enhanced MAO-B activity in SH-SY5Y cells.
  • Iron exposure did not enhance MAO-A activity.
  • The iron-induced increase in MAO-B activity was effectively inhibited by MAO-B specific inhibitors, confirming MAO-B dependence.

Conclusions:

  • MAO-B activity is significantly upregulated by iron exposure in neuronal cells.
  • MAO-B, rather than MAO-A, appears to be a key player in the cellular response to iron stress.
  • These findings suggest MAO-B may function as a critical sensor for iron levels in neurons, potentially offering new therapeutic targets for neurological diseases associated with iron dysregulation.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.0K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K